HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A review of randomized controlled trials using therapeutic apheresis.

Abstract
Apheresis has developed into a common therapeutic modality. The evidence for the clinical benefit of apheresis, however, is generally from uncontrolled and nonrandomized trials. Although the effectiveness of therapeutic apheresis may be established from uncontrolled trials, well-designed, randomized controlled trials provide the best evidence for a clinical benefit because this type of trial design minimizes bias. We assess the evidence for the use of apheresis, the optimal schedules for apheresis, and the replacement solutions used, based on randomized controlled trials. The databases, MEDLINE and EMBASE, and reference lists from relevant articles were searched. The literature search was restricted to articles published in English and included adult patients only. Two of the authors (NS, CK) independently reviewed the citation list to identify reports for retrieval, and the kappa statistic was used to quantify agreement between the reviewers. Articles were included if they used apheresis as an intervention and had clinical endpoints. The quality of the studies was assessed by using a validated instrument. Five hundred and ninety-two citations were identified, and a total of 85 reports were included in this review. There are only a few well-established indications for therapeutic apheresis. Randomized, controlled trials have clearly shown a benefit for patients treated with apheresis who have Guillain-Barre syndrome and patients who have thrombotic thrombocytopenic purpura. A clinical benefit has not been shown for a variety of conditions, including systematic lupus erythematosus, polyarteritis nodosa/Churg-Strauss syndrome, and for the treatment of renal allograft rejection. The effectiveness of apheresis needs to be clarified for several other diseases. As better-designed, randomized trials are performed, the role of apheresis for these indications will be further elucidated.
AuthorsNadine Shehata, Chrisostomos Kouroukis, John G Kelton
JournalTransfusion medicine reviews (Transfus Med Rev) Vol. 16 Issue 3 Pg. 200-29 (Jul 2002) ISSN: 0887-7963 [Print] United States
PMID12075559 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
CopyrightCopyright 2002, Elsevier Science (USA). All rights reserved.
Topics
  • Blood Component Removal (methods)
  • Cardiovascular Surgical Procedures
  • Endocrine System Diseases (therapy)
  • Hematologic Diseases (therapy)
  • Humans
  • Kidney Diseases (therapy)
  • Neurodegenerative Diseases (therapy)
  • Randomized Controlled Trials as Topic
  • Skin Diseases (therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: